businessbriefs
10:44in productionCh. 1 · Origin/ 10:44 · ceiling 15 min
Companies · Strategy

Lupin (company)

1968

Lupin built its business on public health contracts — not disruption, not patents, not venture capital.

Lupin is not a story of startup disruption. It is a story of therapeutic specialisation, state procurement, and incremental geographic expansion — all executed through generic drug manufacturing.

CompaniesStrategyIndiaPhotographyMedicineIndia across the network →
Chapters & takeaways5
  1. 1:08
    Origin

    Lupin is an Indian multinational founded in 1968 in Mumbai by a chemistry professor.

  2. 2:20
    First Market

    Its first commercial product was folic acid and iron tablets made for the Indian government’s mother and child health program.

  3. 3:52
    Therapeutic Dominance

    It specialised in generic anti-TB drugs — once 36% of sales and enough to make it the world’s largest TB drug manufacturer.

  4. 5:12
    Institutional Anchoring

    It embedded itself in India’s industry infrastructure — founding a CSR arm in 1988 and co-founding the Indian Pharmaceutical Alliance in 1999.

  5. 6:47
    US Expansion Play

    Its $880 million acquisition of Gavis and Novel in July 2015 marked a deliberate pivot into the US generics market.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • public health alignment
  • therapeutic specialisation
  • institutional anchoring
  • US acquisition logic
What does not
  • revenue
  • profitability
  • current market share
  • regulatory outcomes
Study it if
  • health policy analysts
  • emerging-market strategists
  • generic pharma operators
Skip it if
  • VC investors seeking growth metrics
  • biotech innovators
  • brand strategists
The written brief1 min read

What the company or idea is

Lupin is an Indian multinational pharmaceutical company founded in 1968 in Mumbai by Desh Bandhu Gupta.

How it actually makes money

Lupin makes money by manufacturing and selling generic drugs across six therapeutic areas: paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

What works

Its focus on high-volume, low-margin therapeutic niches (especially anti-TB drugs, once 36% of sales) and institutional partnerships (e.g., Indian government, Indian Pharmaceutical Alliance) enabled scale.

What does not

The document says nothing about current revenue, profitability, market share, R&D spend, regulatory compliance record, or post-2015 integration outcomes. It offers no evidence of ongoing dominance in TB drugs or current global standing.

What to take from it

Lupin’s early growth was anchored in state-aligned production — folic acid and iron tablets for India’s mother and child health program — not innovation or branding.

Is it worth your time

Yes — if you are studying how Indian pharma scaled globally via public health contracts, therapeutic specialisation, and strategic US acquisitions.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Mack Trucks

Jack and Gus Mack · 1900 · 11:28

A century-old truckmaker that stopped making buses, moved three times, and traded independence for stability — all without becoming a brand relic.

Play nextBack to Companies
11:28